Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients

Mujdat Zeybel1,2,3,†, Ozlem Altay4,†, Muhammad Arit4,†, Xiayu Li4, Hong Yang4, Claudia Fredolini4, Murat Akyildiz3, Burcin Saglam3, Mehmet Gokhan Gonenli3,‡, Dilek Ural5, Woonghee Kim4, Jochen M Schwenk4,†, Cheng Zhang4,6,†, Saeed Shoaie4,7, Jens Nielsen8,†, Mathias Uhlén4, Jan Borén9,† & Adil Mardinoglu4,7,†

Abstract

Nonalcoholic fatty liver disease (NAFLD) refers to excess fat accumulation in the liver. In animal experiments and human kinetic study, we found that administration of combined metabolic activators (CMAs) promotes the oxidation of fat, attenuates the resulting oxidative stress, activates mitochondria, and eventually removes excess fat from the liver. Here, we tested the safety and efficacy of CMA in NAFLD patients in a placebo-controlled 10-week study. We found that CMA significantly decreased hepatic steatosis and levels of aspartate aminotransferase, alanine aminotransferase, uric acid, and creatinine, whereas found no differences on these variables in the placebo group after adjustment for weight loss. By integrating clinical data with plasma metabolomics and inflammatory proteomics as well as oral and gut metagenomic data, we revealed the underlying molecular mechanisms associated with the reduced hepatic fat and inflammation in NAFLD patients and identified the key players involved in the host–microbiome interactions. In conclusion, we showed that CMA can be used to develop a pharmacological treatment strategy in NAFLD patients.

Keywords CMA; multi-omics; NAFLD; systems biology

Introduction

Nonalcoholic fatty liver disease (NAFLD), defined as the hepatic fat accumulation of ≥ 5% unrelated to alcohol consumption and other liver diseases, comprises pathologies that include hepatic steatosis, steatohepatitis, and hepatic fibrosis and cirrhosis (Anstee et al., 2019). NAFLD is closely associated with insulin resistance and metabolic syndrome. Due to the rapid rise in the prevalence of obesity and diabetes; it is the leading cause of chronic liver disease (Estes et al., 2018; Younossi et al., 2018). Globally, at least one in four people have hepatic steatosis (Abeysekera et al., 2020; Bugianesi, 2020).

Current management strategies, including lifestyle modification, increased physical activity, and dietary intervention, have limited adherence and minimal prolonged success (Romero-Gómez et al., 2017; Alferink et al., 2019; Sanyal, 2019). No drugs have been approved to treat NAFLD, and effective treatment options with long-term safety are urgently required. Although research is paving the way for the development of therapeutics, the results of early clinical trials of drugs targeting single pathways have been mostly unsuccessful. Combining compounds that reduce lipid accumulation and hepatocellular injury has been proposed as a more suitable therapeutic strategy for this complex disease (Ertunc & Hotamisligil, 2016; Barbier-Torres et al., 2017, 2020). Targeting multiple pathways is more likely to translate into successful outcomes (Friedman et al., 2018; Mardinoglu, Boren, et al., 2018; Mardinoglu et al., 2019).

A key mechanism in the pathogenesis of NAFLD is inadequate removal of hepatic fat by fatty acid oxidation. Our previous work combining in-depth multi-omics profiling and hepatocyte-specific integrated networks identified three landmark metabolic features of
hepatic steatosis: limited serine availability, reduced de novo glutathione (GSH) synthesis, and altered nicotinamide adenine dinucleotide (NAD) metabolism (Mardinoglu et al., 2014, 2017; Lee et al., 2016).

We hypothesized that NAFLD could be treated with combined metabolic activators (CMAs), including l-carnitine tartrate to facilitate mitochondrial fatty acid uptake from cytosol, the NAD⁺ precursor nicotinamide riboside to induce hepatic mitochondrial β-oxidation and facilitate fatty acid transfer through the mitochondrial membrane, and the potent glutathione precursors L-serine and N-acetylcysteine to reduce oxidative stress (Mardinoglu, Wu, et al., 2018). We further hypothesized that administration of these metabolic activators would promote mitochondrial fatty acid uptake and oxidation and reduce hepatic fat and inflammation. In animal toxicology studies and a human calibration study for CMA, we found that the metabolic activators were well tolerated and increased the activators’ plasma levels and their associated metabolites. Additionally, administration of CMA effectively increased fatty acid oxidation and de novo glutathione generation, as judged by metabolomic and proteomic profiling (Zhang et al., 2020). In this placebo-controlled phase 2 study, we tested our hypotheses and the efficacy and safety of CMA in NAFLD patients by integrating clinical data with plasma metabolomics and inflammatory proteomics as well as oral and gut metagenomics.

Results

Patient characteristics

Of 56 patients screened for the trial, 32 met the eligibility criteria (see Materials and Methods and Supplementary Appendix) and were randomly assigned to receive treatment or placebo. Twenty-four patients were excluded according to the study protocol (Datasets EV1–EV3), and one eligible patient moved to another city before the randomization. Of the remaining 31 eligible patients (24 males and 7 females), 20 were randomly assigned to the CMA group and 11 to the placebo group (Fig 1A). One patient was excluded from analysis as a result of the COVID-19 lockdown. The 30 remaining patients completed the study (Fig 1A). However, because of the COVID-19 lockdown, eight were unable to visit the Day 14 visit’s trial site but completed the final visit on Day 70. These patients have been monitored carefully by phone calls during the study. The patients’ mean age was 40.4 years (25–63 years), and 77.4% were men (Table 1).

Baseline demographic and clinical characteristics did not differ between groups (Table 1, Dataset EV4).

CMA decreases hepatic steatosis and improves clinical parameters

Adherence to the treatment regimen was more than 95% and did not differ between groups. The primary outcome variable, hepatic fat content as judged from the proton density fat fraction estimated by magnetic resonance imaging (MRI-PDFF), was lower on Day 70 than on Day 0 in the CMA group (10%, \(P = 0.028\)) but not in the placebo group (Fig 1B, Datasets EV3 and EV4). After adjustment for weight loss, this difference remained significant in the CMA group (\(P_{\text{adj}} = 0.033\)) (Fig 1, Table 1).

The serum level of alanine aminotransferase (ALT) was lower on Day 70 in both the CMA group (39%, \(P = 0.003\) versus Day 0) and the placebo group (22%, \(P = 0.025\)); however, after weight loss adjustment, the difference remained significant only in the CMA group (\(P_{\text{adj}} = 5.75e-07\), Table 1). On Day 14, the ALT level after weight loss adjustment was significantly lower only in the CMA group (24%, \(P_{\text{adj}} = 0.0015\)) (Fig 1C, Table 1, Dataset EV4). Similarly, the serum level of aspartate aminotransferase (AST) on Day 70 versus Day 0 was lower in both the CMA group (30%, \(P = 0.004\)) and the placebo group (20%, \(P = 0.009\)); however, after weight loss adjustment, the AST level was significantly lower only in the CMA group (\(P_{\text{adj}} = 1.58e-05\)) (Fig 1D, Table 1, Dataset EV4).

The serum uric acid level was lower in the CMA group on both Day 14 (12%, \(P_{\text{adj}} = 0.003\)) and Day 70 (15%, \(P_{\text{adj}} = 1.12e-05\)), both before and after weight loss adjustment (Fig 1E, Table 1, Dataset EV4). The creatinine level on Day 70 was significantly decreased only in the CMA group (8%, \(P_{\text{adj}} = 0.0007\)), both before and after weight loss adjustment (Fig 1F, Table 1, Dataset EV4). The serum levels of uric acid and creatinine did not change in the placebo group at either time point (Table 1, Dataset EV4). Systolic blood pressure on Day 70 was 5% lower in the CMA group (\(P = 0.023\)), whereas in the placebo group, it was unchanged and diastolic blood pressure had increased (\(P = 0.038\) (Dataset EV4).

CMA alters plasma metabolites

To characterize the patients and reveal the underlying molecular mechanisms associated with the decrease in liver fat and improvement in clinical parameters in the CMA group, we generated untargeted metabolomics data from plasma samples and measured the levels of 1,032 metabolites (Dataset EV5). After excluding metabolites with missing values in >50% of samples, 929 metabolites were analyzed (Dataset EV5). Metabolites, whose levels on Day 70 and Day 14 versus Day 0 differed significantly both before and after weight loss adjustment, are listed in Dataset EV6; those that differed between groups are listed in Dataset EV7.

Plasma levels of serine, nicotinamide, and carnitine, which are directly associated with CMA, and of metabolites indirectly associated with CMA were significantly higher on Day 70 than on Day 0 in the CMA group (Fig 2A, Dataset EV6), and those levels were significantly higher than in the placebo group (Dataset EV7). Specifically, the plasma levels of N1-methyl-4-pyridone-3-carboxamide, N1-methyl-2-pyridone-5-carboxamide, and 1-methylnicotinamide (associated with NR and NAD⁺ metabolism); of N-acetylglycine, N-palmitoylserine, N-oleoylserine, and N-stearoylserine (associated with serine and glycine metabolism); and of deoxycarnitine, acetyl carnitine, and butyrylcarnitine (associated with carnitine metabolism) were significantly higher on Day 70 than on Day 0 in the CMA group (Dataset EV6). On the other hand, we found that the plasma level of cysteine associated with NAC showed tendency (\(P = 0.052\)) to be downregulated on Day 70 versus Day 0 in the CMA group (Dataset EV6). On the other hand, we found that the plasma level of cysteine associated with NAC showed tendency (\(P = 0.052\)) to be downregulated on Day 70 versus Day 0 in the CMA group (Dataset EV6). On the other hand, we found that the plasma level of cysteine associated with NAC showed tendency (\(P = 0.052\)) to be downregulated on Day 70 versus Day 0 in the CMA group (Dataset EV6).
Figure 1. CMA improves liver fat and clinical parameters.

A Study design for testing the effects of CMA in NAFLD patients.

B–F Differences in clinical variables including (B) liver fat, plasma levels of (C) ALT, (D) AST, (E) uric acid, and (F) creatinine are presented in the CMA and placebo groups on Days 0, 14, and 70 after weight loss adjustment. Adj. P indicates P value after weight loss adjustment. Statistical significance is defined based on paired Student’s t-test. P < 0.05. The boxes show the distribution of the clinical parameters in different groups. The bottom and top of the boxes represent the 25th and 75th percentiles. The central band represents the median value. The whiskers represent the minimum and maximum values that are not outliers, and dots represent outlier values. The sample sizes on Day 0, 14, or 70 were marked in each boxplot.
We found that 110 metabolites differed significantly on Day 70 versus Day 0 ($P < 0.05$) in the CMA group; 44 metabolites were involved in lipid metabolism (Fig EV1), and 66 metabolites were involved in amino acids and other parts of the metabolism (Fig 3A, Dataset EV6). Of the 66 metabolites that were significantly different on Day 70 versus Day 0 in the CMA group, 4 of them were significantly different in both groups (Fig 3B), 62 of them were significantly different in only CMA group (Fig 3C), and 27 of them were significantly different only in the placebo group (Fig 3D). Previously, we found that the increased plasma levels of kynurenine and kynurenate were associated with high hepatic fat (Mardinoglu, Wu, et al., 2018). In a one-day clinical study of the acute effect of CMA, we found that the increased plasma levels of kynurenine and kynurenate were significantly decreased (Zhang et al., 2020). In the current study, plasma levels of kynurenate (Fig 3B) and kynurenine (Fig 3C) were significantly lower on Day 70 versus Day 0 in the CMA group both before and after weight loss adjustment (Dataset EV6). On the other hand, the kynurenate plasma level was significantly increased on Day 70 versus Day 0 in the placebo group (Fig 3B). Moreover, we found that the plasma level of 3-amino-2-piperidone associated with the urea cycle; arginine and proline metabolism were significantly decreased on Day 70 versus Day 0 in the CMA group, whereas its plasma level was significantly increased in the placebo group (Fig 3B).

Our analysis also revealed decreased metabolism of purine and xanthine in the CMA group on Day 70. Plasma levels of urate, xanthine, hypoxanthine 5-acylamino-6-amino-3-methyluracil, 1,7-dimethylurate, and theophylline were significantly reduced in the CMA group on Day 70 (Fig 3C, Dataset EV6). Consistent with these findings, plasma uric acid levels were significantly decreased in this group. N-trimethyl-5-aminovalerate (TMAVA) was the most significantly reduced metabolite in the CMA group on Day 70, both before and after weight loss adjustment (Fig 3C, Dataset EV6) and was significantly lower than in the placebo group (Dataset EV7). TMAVA is linked to intestinal microbes and associated with lysine metabolism and is one of the best predictors of microalbuminuria (Haukka et al., 2018). In a previous study, the plasma level of TMAVA was significantly increased in NAFLD patients (Zhao et al., 2020).

Enterococcus faecalis and Pseudomonas aeruginosa are responsible for metabolizing trimethyllysine to TMAVA, which was further modulated by antibiotic treatment in a mouse model (Zhao et al., 2020). We also found that the plasma level of N,N,N-trimethyl-alanlyproline betaine (TMAP) was significantly downregulated in the CMA group on Day 70, even after weight loss adjustment (Fig 3C, Dataset EV6), as were creatinine levels (Fig 1F, Table 1, Dataset EV4). TMAP has been described as a novel potential biomarker of the dialytic clearance that can accurately define kidney function (Velenosi et al., 2019).

CMA treatment correlated significantly with the plasma levels of serine, glycine, gamma-glutamylglycine, carnitine, TMAVA, 1-methylnicotinamide, N1-methyl-4-pyridone-3-carboxamide, and N1-methyl-2-pyridone-5-carboxamide (Fig 2B, Dataset EV8). But none of these metabolites correlated significantly with the plasma cysteine level, indicating that cysteine utilization differs from that of other metabolites in the CMA.

### CMA reduces inflammation

Plasma levels of 96 inflammatory protein markers were measured with the plasma proteome profiling platform Proximity Extension Assay (PEA) using an inflammation panel quantifying the plasma level of target proteins. After quality control and exclusion of proteins with missing values in more than 50% of samples, 72 proteins were analyzed (Dataset EV9). Proteins whose levels differed significantly between the visits in the CMA and placebo groups are listed in Dataset EV10. The plasma levels of CD8A, CSF-1, CCL23, FGF-21, and oncostatin-M (OSM) were significantly decreased in both groups (Fig 4A, Dataset EV10); however, no significant changes in plasma levels of inflammation-related proteins were found in the placebo group (Dataset EV10).
Figure 2.
plasma levels of CSF-1, OSM, and FGF-21 are significantly associated with hepatic steatosis (Lovric et al., 2018). The findings in this study are in agreement with our previous studies. The plasma levels of FGF-21 and CCL23 rapidly decreased in our 1-day CMA study after eliminating the effect of the fasting (Zhang et al., 2020), and the plasma level of FGF-21, CCL23, and CSF-1 had significantly reduced in 1-week carbohydrate-restricted diet study (Mardinoglu, Wu, et al., 2018).

We assessed the associations between the plasma level of the significant proteins and the individual metabolic activators and found that CSF-1 and OSM levels are negatively correlated with carnitine and serine levels (Fig 4B, Dataset EV11). Additionally, nicotinamide is also negatively correlated with CSF-1 levels (Fig 4B, Dataset EV11).

We finally identified links between proteins whose plasma levels changed significantly and plasma metabolites (Fig 4C, Dataset EV12). FGF-21 correlated with the glycine conjugate of C10H14O2, 2-hydroxyoctanoate, and N2,N2-dimethylguanosine and correlated negatively with bilirubin degradation products, 2-piperidinone, and carboxyethyl-GABA.

CMA alters gut and oral microbiome

The alterations in the gut microbiome have been associated with the NAFLD (Aron-Wisnewsky et al., 2020). In our study, we collected feces and saliva samples to study the effect of the CMA on the gut and oral microbiome and revealed the interactions between the host and microbe interactions during the CMA treatment.

We first compared the differences in the species’ abundances between Day 70 versus Day 0 in the CMA and placebo groups in the gut microbiome. We found that abundances of Proteobacteria (Neisseria flavigena), Actinobacteria (Rothia mucilaginosa, Adlercreutzia equolifaciens, Asaccharobacter celatus, Collinsella aerofaciens, Bifidobacterium adolescentis, and Actinomyces sp ICM47), and Firmicutes (Streptococcus mitis, Streptococcus sanguinis, Streptococcus parasanguinis, Roseburia auris, Roseburia hominis, and Eubacterium hallii) were significantly decreased. However, in the placebo group species belong to Firmicutes (Firmicutes bacterium CAG 83 and Oscillobacter sp 57 20) and Bacteroides vulgatus were significantly reduced (Fig 5A, Datasets EV16 and EV17). Numerous studies indicated that Actinobacteria and Proteobacteria abundance was increased in NAFLD compared with healthy controls, at the level of phylum (Guohong et al., 2019). Furthermore, increased Firmicutes-to-Bacteroidetes ratio has been stated as a feature of obesity-related NAFLD, but subsequent studies have shown inconsistent results, which still needs further research (Porras et al., 2018).

Next, we compared the abundances of the species between CMA versus placebo groups on Day 70 in the gut microbiome. We found that the abundance of the butyrate-producing species (Lawsonibacter asaccharolyticus, Eubacterium remus, and Eubacterium siraeum) was significantly increased in the CMA group (Fig 5B, Datasets EV16 and EV17). Butyrate is a preferred energy source for gut epithelial cells, and it plays a vital role in maintaining health in humans. Notably, the abundance of acetaldehyde producer Rothia mucilaginosa was significantly downregulated in the gut microbiome of CMA group on Day 70 versus Day 0 (Fig 5A) and lower than the placebo group on Day 70 (Fig 5B, Datasets EV16 and EV17).

Similarly, we compared the differences in the species’ abundances between Day 70 versus Day 0 in the CMA and placebo groups in the oral microbiome. We found that the abundance of the specific species of Proteobacteria (Cardiobacterium hominis), Bacteroidetes (Prevotella macalosa), and Actinobacteria (Corynebacterium matruchotii and Actinobuculum sp oral taxon 183) was significantly decreased in the CMA group (Figs 5C and EV2, Dataset EV18). We also found increased abundance of Actinomyces sp oral taxon 181 and reduced abundance of Neisseria sicca between CMA versus placebo groups on Day 70 in the oral microbiome (Fig 5D, Dataset EV18).

We evaluated the association of the plasma levels of metabolites directly related to CMA with the abundance of species in the gut microbiome (Fig 5E) and oral microbiome (Fig EV2) and found that Faecalibacterium prausnitzii is positively correlated with CMA related metabolites, namely cysteine, cysteinyl glycine, sarcosine, and N1-methylinosine (Fig 5E, Dataset EV17). We also found that plasma cysteine levels are significantly positively correlated with the abundance of species associated with Firmicutes (Roseburia faecis and Oscillobacter sp 57 20) and Bacteroidetes (Bacteroides ovatus and Bacteroides fragilis). Additionally, we observed that the plasma levels of N1-methyl-4-pyridone-3-carboxamide and N1-methyl-2-pyridone-5-carboxamide are significantly positively correlated with the abundance of Alistipes shahii and negatively correlated with the abundance of Bacteroides cellulosolityicus and Fusicatenibacter saccharivorans (Fig 5E, Dataset EV17).

Changes in the gut microbiome are linked to inflammation by triggering molecules involving interleukins and other cytokines (Schirmer et al., 2016). An increased abundance of Coprococcus eutactus and decreased abundance of Bacteroides faecis, Bacteroides dorei, Bacteroides xylanisolvens, and Barnesiella intestihominis in the gut microbiome were associated with FGF-21 levels (Fig 4D, Dataset EV17). In the oral microbiome, we found that the abundances of Prevotella jejuni and Alloprevotella tannerae were significantly negatively correlated with the plasma level of FGF-21.
Moreover, we found that increased abundance of *Prevotella copri* and *Neisseria sicca* and decreased abundance of *Neisseria elongate* and *Haemophilus parainfluenzae* in the oral microbiome associated with the plasma level of CCL23, of which gene expression level was significantly upregulated in NASH patients (Hart *et al.*, 2017) (Fig 4E, Dataset EV18). Interestingly, increased abundances of *Faecalibacterium prausnitzii* and *Bacteroides fragilis* in the gut microbiome were positively correlated with the plasma level of CD8A, indicating the key role of the microbiome in the modulation of CD8 T-cell responses (Fig 4D, Dataset EV17).

Even though the oral and gut microbiome are distinct, a body of evidence claimed a strong relationship between these microenvironments due to the transfer of oral members to gut by a constant flow...
Figure 4.
of saliva and ingestion (Schmidt et al, 2019). Therefore, we evaluated the species’ correlation in feces and saliva microbiome and revealed a significant positive correlation between species pairs, where only two pairs were negatively correlated (Fig EV3). Interestingly, we found that the abundance of the species belongs to the Prevotella genus in the oral microbiome and the species belong to Bacteroides genus in the gut microbiome are affected apparently from each other’s abundance (Fig EV3).

The associations between clinical variables and multi-omics data

To study the link between improved clinical parameters and metabolism, we determined the significant correlations between improved clinical variables (e.g., hepatic fat, ALT, AST, and uric acid) and various metabolites (Fig 6A, Dataset EV13). The plasma level of cysteine-glutathione disulfide, iminodiacetate, 4-hydroxycchlorothalolin, and arachidonylecholine significantly and negatively correlated with hepatic fat (Fig 6A, Dataset EV13). Of these metabolites, cysteine-glutathione disulfide significantly and negatively correlated with ALT, AST, and uric acid levels, indicating that glutathione metabolism has a key role in improving liver functions in NAFLD patients.

We assessed the associations between improved clinical parameters and inflammation by identifying the significant correlations between improved clinical variables (e.g., hepatic fat, ALT, AST, and uric acid) and various inflammation-related proteins (Fig 6B, Dataset EV14). We observed a positive correlation between the liver fat and the plasma level of CDCP1, CCL23, TNFSF14, and FGF-21; the AST level and the plasma level of CSF-1 and CDCP1; the ALT level and the plasma levels CDCP1, CSF-1 and FGF-21; the uric acid level and plasma level of TNFSF14; and the creatinine level and plasma levels of OSM and EN-RAGE. Additionally, we found a negative correlation between the levels of ALT and AST and plasma level of CCL28, which is significantly positively correlated with the plasma level of serine.

Correlation analysis between the improved clinical variables and the abundances of key discriminatory microbial species showed that the abundances of Prevotella copri in gut microbiome were positively correlated with liver fat, AST, ALT, and systolic blood pressure level (Fig 6C, Dataset EV17). Additionally, the abundance of Prevotella sp CAG 279, Eubacterium sp CAG 38, Bacteroides uniformis, and Bacteroides eggerthii are other positively correlated species with the liver fat. In contrast, the abundance of Fusocatenibacter saccharivorans and Prevotella sp CAG 279 is negatively correlated with liver fat (Fig 6C, Dataset EV17). We also found that the abundance of Ruminococcus bicirculans was significantly correlated with ALT and AST levels; however, the abundance of Allistipes shahii showed a negative correlation with both ALT and AST levels (Fig 6C, Dataset EV17). Of note, we found significant negative correlation Eubacterium rectale with ALT levels and Faecalibacterium prausnitzii with AST levels; both are well-known species associated with healthy gut microbiome (Fig 6C, Datasets EV16 and EV17).

Several studies reported that the oral microbiota reflects changes in gut microbiota’s dysbiosis, and it might be indicator for liver pathologies (Baja et al, 2015). In our study, the evaluation of oral microbiome showed that the abundances of Veillonella infantantium and Prevotella jejuni are positively and the abundances of Capnocytophaga leadbetteri are negatively correlated with liver fat; AST levels were positively correlated with the abundances of Aggregatibacter segnis and Haemophilus sp HMCST1H05; ALT levels were negatively correlated with the abundances of Prevotella oral taxon 306 (Fig 6D, Dataset EV18).

It has been shown that gut microbiota plays significant roles in uric acid metabolism. Here, we found that the abundances of Bacteroides coprocola and Proteobacteria bacterium CAG 139 in the gut microbiome and Neisseria subflava in the oral microbiome were significantly positively correlated with the uric acid levels. In contrast, the abundances of Bacteroides ovatus, Butyrivibrio crossotus, and Parasutterella excrementinis in the gut microbiome and the abundances of Gemella haemolysans in the oral microbiome were significantly negatively correlated (Fig 6C and D, Datasets EV16–EV18). We also found that the abundances of the Fusobacterium periodonticum and Porphyromonas somerae, opportunistic pathogens in the oral microbiome, were significantly positively correlated to the urea levels (Fig EV2A). Interestingly, creatinine levels correlated with increased abundances of Prevotella copri and Neisseria flavescens and decreased abundances of Prevotella nigrescens and Veillonella parvalva in the oral microbiome (Fig 6D, Dataset EV18). The abundances of Bacteroides fragilis and Faecalibacterium prausnitzii in the gut microbiome are negatively correlated with creatinine levels (Fig 6C, Dataset EV17).

Integrative multi-omics analysis

We generated an integrative multi-omics network based on clinical variables, proteomic, metabolomic, and metagenomic data to show the functional relationship between analytes within and between omics data. The filtered network (edges FDR < 0.05) can be viewed at iNetModels (http://iNetModels.com), an open-access interactive web platform for multi-omics data visualization and database (Arif et al, 2021). We overlapped the statistically altered metabolites, proteins, and clinical variables to the sub-network of the metabolic activators and liver fat, as primary clinical variable targeted by CMA (Fig 7A). Furthermore, we performed a centrality analysis of the
Figure 5. CMA alters gut and oral microbiome.

A–D Scatter plot with linear regression line and heatmap show log2FC-based alterations of the significantly different species in the (A) gut microbiome between CMA and placebo groups on Day 70 versus Day 0; (B) gut microbiome between Day 70 versus Day 0 in the CMA and placebo groups; (C) oral microbiome between CMA and placebo groups on Day 70 versus Day 0; (D) oral microbiome between Day 70 versus Day 0 in the CMA and placebo groups. Each dot represents a species, and it has been colored according to its corresponding phylum. Asterisks indicate statistical significance based on paired Wilcoxon signed-rank test. P < 0.05. Log2FC: log2(fold change).

E Heatmaps show the correlations between the plasma levels of metabolites (other than lipids) and the abundance of the species in the gut microbiome. Asterisks indicate statistical significance based on Spearman correlation analysis. P < 0.05. Cor. Coeff: correlation coefficient.
Figure 6. Associations between the clinical data and omics data. 

A–D  Heatmap shows the association between the plasma level of clinical variables including liver fat, ALT, AST, uric acid, and creatinine with (A) plasma level of 10 most significant metabolites, (B) plasma level of 10 most significant inflammation-related proteins, (C) the abundance of the species in gut microbiome, and (D) the abundance of the species in oral microbiome. AST, aspartate aminotransferase; ALT, alanine transaminase. Asterisks indicate statistical significance based on Spearman correlation analysis. $P < 0.05$; Cor. Coeff: correlation coefficient.
filtered network to identify the most central analytes. We identified carnitine as the most prominent metabolic activator. We also observed that top 20-degree metabolites were dominated by lipid structures (sphingomyelin, phosphatidylinositol/choline, diacylglycerol, and fatty acids), gamma-glutamylisoleucine, and retinol (Vitamin A). For the clinical variables, the level of uric acid, that was shown to be downregulated in the CMA group, was identified as one of the top 5 most connected clinical nodes.

Moreover, we observed that the abundance of the *Roseburia faecis* (significantly downregulated in the CMA group) is significantly negatively correlated with the plasma level of serine and carnitine (Fig 7B). Based on these results, the multi-omics integrative network analysis complemented and strengthened the single-omics analysis findings. We also observed that serine and carnitine play key roles among the metabolic activators in improving the clinical outcome.

Figure 7. Integrating omics data based on network analysis.
A Neighbors of the CMA, including serine, carnitine, nicotinamide, and cysteine, and two important clinical variables (liver fat and uric acid) are presented based on the multi-omics network analysis. Only analytes that are significantly altered in CMA Day 70 versus Day 0 are highlighted.
B First degree of microbial neighbors of the CMA and two important clinical variables (liver fat and uric acid) are presented based the multi-omics network analysis. Full networks can be found in iNetModels (http://inetmodels.com).
Safety

Both the CMA and placebo treatments were generally well tolerated. Eighteen patients (12 in the CMA group and 6 in the placebo group) reported only mild-to-moderate adverse events, including nonspecific gastrointestinal (33%) and musculoskeletal (20%) symptoms, and all patients decided to complete the study (Dataset EV15). Gastrointestinal symptoms in three patients in the placebo group and one in the CMA group were associated with the intervention, and their drug doses were reduced to one per day.

Discussion

Based on data-driven modeling and systems biology analysis, we found that administration of CMA may increase the liver’s fat oxidation, enhance the mitochondrial function in the cells, and reduce oxidative stress. To test this hypothesis in a clinical setting, we performed a randomized, placebo-controlled phase 2 study to investigate the efficacy and safety of CMA in NAFLD patients. We observed improvements on clinical variables, plasma metabolomics, inflammatory proteomics, and oral/gut microbiome after CMA treatment in NAFLD patients (Fig 8). We found that CMA (10%) ameliorates the hepatic fat content assessed by MRI-PDFF and reduces serum ALT (39%) and AST (30%) levels after 70 days. We also observed that CMA reduces plasma levels of CD8A, CSF-1, CCL23, and OSM, as shown by plasma proteomic analysis, indicating that CMA attenuates hepatic inflammation. The positive results were not linked to significant weight loss in the CMA group.

Analysis of untargeted metabolomics data confirmed the expected biological outcomes of CMA treatment. Levels of plasma N1-methyl-2-pyridone-5-carboxamide and 1-methylnicotinamide were increased, suggesting that nicotinamide riboside provides sufficient substrate and NAD⁺ for mitochondrial activation. These metabolites have shown to be increased in a recent study, supporting the insulin-sensitizing ability of the nicotinamide mononucleotide, another NAD⁺ intermediate, in skeletal muscle of prediabetic women (Yoshino et al, 2021). Plasma levels of N-acetylglycine, N-palmitoylsersine, N-oleylserine, and N-stearoylsersine were also increased, suggesting that CMA treatment...
improves the serine deficiency associated with hepatic steatosis. More importantly, fatty acid oxidation and carnitine metabolism were remarkably facilitated, as judged from the robust plasma levels of deoxycarnitine, acetylcarnitine, and butyrylcarnitine. Moreover, after weight loss adjustment, the levels of tryptophan metabolites, including kynurenate, kynurenine, and tryptophan betaine, decreased significantly after CMA treatment.

Unexpectedly, CMA rapidly reduced the plasma level of uric acid and associated metabolites (Fig EV4). Uric acid stimulates hepatic steatosis either directly or by activating NLRP3 inflammasomes (Lanaspa et al., 2012; Wan et al., 2016). Although the extent to which uric acid reduction contributed to the regression in hepatic steatosis is unclear, it likely had an additive effect. How might CMA reduce serum uric acid levels in overweight and obese subjects? A recent study revealed a strong association with uric acid and 1-methylhistidine levels, which is significantly decreased with CMA therapy (Pietzner et al., 2021). Another possible explanation is that the glycine derived from serine lowers uric acid levels by stimulating uricosuria (Oshima et al., 2002). Further clinical studies that include hyperuricemic patients will be required to determine whether this effect can be generalized to treat patients with hyperuricemia.

The cellular levels of NAD⁺ and GSH are fundamental factors related to the metabolic conditions and the risk for mortality (Miller et al., 2020; Silvagno et al., 2020). Depleted GSH can be restored by administration of NAC, serine, and glycine which can be synthesized through the interconversion of serine (Sim et al., 2014). Two other components of CMA including carnitine and NR, which stimulate the transfer of fatty acids from the cytosol to mitochondria, are also depleted in liver diseases (Hagen et al., 1998; Bieganowski & Brenner, 2004; Trammell et al., 2016; Salic et al., 2019; Savic et al., 2020). Overall improvement of clinical homeostasis reduces oxidative injury and improves bioenergetics, thereby is more likely to have successful outcomes (Cummings et al., 2020). According to this, we recently demonstrated the efficacy of CMA for different metabolic conditions in a short-term (14 days) phase 2/3 COVID-19 clinical trials (Altay et al., 2021) and two longer-term (12 weeks) phase 2 Alzheimer’s disease (AD) (preprint: Yulug et al., 2021a) and Phase 2 Parkinson’s disease (PD) (preprint: Yulug et al., 2021b) clinical trials. Notably, we observed the administration of CMA decreased the levels of ALT and creatinine in all short-term and longer-term clinical trials and it decreased the level of uric acid in longer-term AD and PD phase 2 clinical trials.

The direct or indirect impact of the microbiome on NAFLD remains poorly understood, but numerous human and animal studies have confirmed the contribution of intestinal microbiota as a driver through the compositional alterations, changes in the levels of microbiota-derived metabolites, and loss of gut barrier integrity (Altay et al., 2019; Aron-Wisnewsky et al., 2020). Even though the inconsistent results have been obtained for patient-derived microbiome composition analyses, overgrowth of the Proteobacteria and Actinobacteria phyla and the increased Firmicutes/Bacteroidetes ratio have been shown as common markers of dysbiosis (Aron-Wisnewsky et al., 2020; Magne et al., 2020). In this study, we comprehensively characterized the gut and oral microbiome in NAFLD patients before and after administration of CMA. We observed a significant decrease in the abundance of species belonging to Proteobacteria, Actinobacteria, and Firmicutes in the CMA group after 70-day therapy. Additionally, the main end products of bacterial metabolism are short-chain fatty acids which especially butyrate is shown to reduce intestinal inflammation (Segain et al., 2000). In our study, well-known butyrate-producing species are increased in the CMA group. Our results collectively indicated that CMA induced literature supported beneficial alterations such as positive correlation with the abundances of Faecalibacterium prausnitzii (Munukka et al., 2017; Grabherr et al., 2019), Roseburia faecis (Tamanai-Shacoori et al., 2017), or butyrate producers (Boesmans et al., 2018; Baxter et al., 2019). In addition to identifying the key species, defining the distinct signatures of the microbiome and liver-related clinical parameters in the well-defined patient cohort is valuable in discovery of new biomarkers for NAFLD.

A few limitations of the study need to be considered. First, the study was designed to include 45 participants; however, because of COVID-19 restrictions, only 32 subjects were enrolled. Moreover, only 7 female subjects (3 from CMA and 4 from placebo group) remained in the sample pool, which hinder the possibility to perform sex-specific analysis. Second, patients who had type 2 diabetes or dyslipidemia or were taking anti-diabetic medications were excluded, which resulted in a more homogenous clinical trial group. Third, hepatic fat content and inflammation were assessed by MRI-based methods and plasma inflammatory protein markers rather than liver histology. Our findings warrant a clinical trial in patients with biopsy-proven nonalcoholic steatohepatitis to delineate the effects CMA on hepatic injury and inflammation.

The safety profile of CMA in these patients was consistent with the results of our previous one-day calibration study and clinical trials, including only a single component of the CMA (Zhang et al., 2020). Our present study showed that CMA was safe and well-tolerated in NAFLD patients, and no major safety concerns were identified. In conclusion, CMA significantly reduced hepatic fat content and serum markers of hepatic injury in 10 weeks. These findings suggest that targeting multiple pathways by CMA is a potentially effective therapeutic strategy for NAFLD.

Materials and Methods

Trial design and oversight

Patients for this randomized, placebo-controlled, phase 2 study were recruited at the Koc University Hospital, Istanbul, Turkey (Dataset EV1). The trial was conducted following Good Clinical Practice guidelines and the principles of the Declaration of Helsinki. An independent external data monitoring committee oversaw the safety of the participants and the risk–benefit analysis. Written informed consent was obtained from all participants before trial-related procedures were initiated. The study was approved by the ethics committee at Koc University (Decision No: 2018.351.1RB1.043). The study was registered at https://eudact.ema.europa.eu/ with the accession number EudraCT_2018-000894-59 and at https://clinicaltrials.gov/ with the accession number NCT04330326.
Participants

Overweight or obese patients 18–70 years of age were enrolled in the trial if they were diagnosed with NAFLD and met all the inclusion criteria: body mass index > 27 kg/m², triglycerides ≤ 354 mg/dl, low-density lipoprotein cholesterol ≤ 175 mg/dl, and increased hepatic fat (> 5.5%). Patients were excluded if they carried the PNPLA3 I148 M (homozygous for I148 M), had ALT or AST levels > 3-fold higher than the upper limit of normal, or had taken oral antidiabetics, including metformin, within 3 months. The inclusion and exclusion criteria are detailed in the Supplementary Appendix.

The main characteristics of the study participants are presented in Table 1 and Dataset EV2.

Randomization, interventions, and follow-up

Patients were randomly assigned to CMA or placebo (2:1). Patient information (patient number, date of birth, initials) was entered into the web-based randomization system, and the randomization codes were entered into the electronic case report form.

CMA treatment was given for 70 days after the initial diagnosis of high hepatic fat by MRI-PDFF. Patients in the treatment group took one dose of CMA (3.73 g L-carnitine tartrate, 1 g nicotinamide riboside, 12.35 g serine, and 2.55 g N-acetyl-l-cysteine) daily for the first 14 days (after dinner) and two doses daily for the next 56 days (after breakfast and dinner). Further information is provided in the Supplementary Appendix.

The subjects returned to the study center for complete follow-up evaluations, including body composition analysis and adverse events recording. Hepatic fat was determined by MRI-PDFF on Days 0, 14, and 70. Plasma samples for proteomic and metabolomic analyses were obtained on Days 0, 14, and 70. After Day 70, subjects stopped taking their drugs (Dataset EV1).

Study outcomes

The study’s primary objective was to assess the difference in hepatic fat content, quantified by MRI-PDFF, between subjects treated for 70 days with CMA or placebo (Dataset EV3). The secondary objectives were to assess the tolerability and safety profile of CMA, as judged by laboratory analyses and physical parameters (Dataset EV4), and to examine additional efficacy data, as evaluated by biochemical, metabolomic, and proteomic analysis.

The number and characteristics of adverse events, serious adverse events, and treatment discontinuation due to study drugs were reported from the beginning of the study to the end of the follow-up period as key safety endpoints (Supplementary Appendix). Changes in vital signs (systolic and diastolic blood pressures, pulse, respiratory rate, body temperature, pulse oximetry values), baseline values, and treatment status were recorded by phone contacts between the visits. A complete list of endpoints is provided in the Supplementary Appendix.

Untargeted metabolomic analysis

Plasma samples were collected on Days 0, 14, and 70 (Datasets EV5–EV8) for nontargeted metabolite profiling by Metabolon (Durham, NC). The samples were prepared with an automated system (MicroLab STAR, Hamilton Company, Reno, NV). For quality control purposes, a recovery standard was added before the first step of the extraction. To remove protein and dissociated small molecules bound to protein or trapped in the precipitated protein matrix and to recover chemically diverse metabolites, proteins were precipitated with methanol under vigorous shaking for 2 min (Glen Mills GenoGrinder 2000) and centrifuged. The resulting extract was divided into four fractions: one each for analysis by ultraperformance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) with positive ion-mode electrospray ionization, UPLC-MS/MS with negative ion-mode electrospray ionization, and gas chromatography-mass spectrometry; one fraction was reserved as a backup.

Inflammatory protein markers

In the plasma samples, inflammatory protein markers were determined with the Olink Inflammation panel (Olink Bioscience, Uppsala, Sweden) (Datasets EV9–EV11). Briefly, each sample was incubated with 92 DNA-labeled antibody pairs (proximity probes). When an antibody pair binds to its corresponding antigens, the corresponding DNA tails form an amplicon by proximity extension, which can be quantified by high-throughput, real-time PCR. Probe solution (3 μl) was mixed with 1 μl of sample and incubated overnight at 4°C. Then, 96 μl of extension solution containing an extension enzyme and PCR reagents for the pre-amplification step was added. The extension products were mixed with detection reagents and primers and loaded on the chip for qPCR analysis with the BioMark HD System (Fluidigm Corporation, USA). To minimize inter and intra-run variation, the data were normalized to both an internal control and an interplate control. Normalized data were expressed in arbitrary units (Normalized Protein eXpression, NPX) on a log2 scale and linearized with the formula 2^NPX. A high NPX indicates a high protein concentration. The limit of detection, determined for each of the 92 assays, was defined as three standard deviations above the negative control (background).

Statistical analysis

Values are expressed as the mean ± standard deviation (SD) (continuous variables) or as n (%) (categorical variables). Safety and exploratory efficacy endpoints were analyzed in all randomized patients who received CMA. Differences in clinical and physiological variables between time points were analyzed by paired t-test, followed by one-way ANOVA to find shifts between CMA and placebo groups at each time point. Missing values were removed in a pairwise fashion.

For analysis of plasma metabolomics, raw data from Day 14 and Day 70 in both groups were scaled to data on Day 0. Metabolite changes in the CMA group versus the placebo group over time (Dataset EV6) were analyzed by one-way ANOVA. Differences between the CMA and placebo groups on Day 0, Day 14, and Day 70 were also calculated (Dataset EV7). The calculation was done by pairing each subject from different visits and adjusted for weight loss in a linear model using the limma package in R (v4.0.2). Differences were considered significant at \( P < 0.05 \).
For analysis of plasma proteomics, raw data from Day 14 and Day 70 were scaled to data on Day 0. Subsequently, ANOVA was used to calculate the CMA group changes versus placebo over time (Dataset EV10). \( P < 0.05 \) was considered statistically significant.

Finally, Spearman correlation analysis (false discovery rate < 0.05) was used to analyze the association between individual components of CMA and other metabolites (Dataset EV8) and between the significantly altered clinical parameters (e.g., hepatic fat and plasma levels of ALT, AST, uric acid, and creatinine) and other metabolites (Dataset EV13). Spearman correlation analysis was also used to study the associations between the plasma protein levels and the plasma metabolite levels (Dataset EV12).

**Metagenomic data analysis**

Fresh stool and saliva specimens were collected and preserved using DNA/RNA Shield Fecal Collection Tubes (Zymo Research, Irvine, CA) and DNA/RNA Shield Collection Tube (Zymo Research, Irvine, CA), respectively. Saliva samples were collected during the visit; however, stool collection kits were provided to the patients and advised to collect stool samples in the last 24 h of the visit. DNA extractions from the fecal samples were done using QIAamp Power-Fecal Pro DNA Kit (Qiagen, Hilden, Germany) and the saliva samples using QIAamp DNA Microbiome Kit (Qiagen, Hilden, Germany). All protocol procedures were performed according to the manufacturer’s instructions. Quantification of extracted DNA was determined fluorometrically on the Qubit® 3.0 Fluorometer (Thermo Fisher Scientific, United States) using the QubitTM dsDNA HS Assay Kit. DNA purity was determined via 260/280 and 260/230 ratios measured on the NanoDrop 1000 (Thermo Fisher Scientific, United States). The SMARTer Thruplex DNA-Seq (Takara Bio) was used for library preparation (Option:350 bp; Category: low input). Samples were sequenced on NovaSeq6000 (NovaSeq Control Software 1.7.0/RTA v3.4.4) with a 151nt (Read1)-10nt(Index1)-10nt(Index2)-151nt (Read2) setup using “NovaSeqXp” workflow in “S4” mode flow cell. The Bcl to FastQ conversion was performed using bcl2fastq v2.20.0.422 from the CASAVA software suite. The quality scale used is Sanger/phred33/illumina 1.8+.

Raw paired-end metagenomic data were analyzed using Metaphlan3 (Beghini et al, 2021) to extract each sample’s taxonomic profiles. The abundant data were then analyzed using the Wilcoxon rank-sum test to identify the species difference between subjects with no steatosis compared with the other groups. Spearman correlation analysis was used to analyze the associations between selected analytes and the taxonomic abundance data. The correlation between oral and gut metagenomics data were performed for the species with abundance > 1% in at least 5 subjects. The SciPy package was used. All analyses were done using Python 3.

**Generation of multi-omics network**

Multi-omics network was generated based on the Spearman correlations, and the significant associations (FDR < 0.05) are presented. The analyses were performed with the SciPy package in Python 3.7. Centrality analysis on the network was performed using iGraph Python.

**Data and materials availability**

All clinical, biochemical, metabolomic, and proteomic data associated with this study are available in the main text or the supplementary materials. The raw oral and gut metagenomic data have been deposited at the European Genome-phenome Archive (EGA) which is hosted at the EBI and the CRG, under accession number EGA: EGAS00001005616 (https://ega-archive.org/studies/EGAS00001005616).

**Expanded View** for this article is available online.

**Acknowledgements**

This work was financially supported by ScandiBio Therapeutics and Knut and Alice Wallenberg Foundation (Grant no. 72110). The authors would like to thank ChromaDex (Irvine, CA, USA) for providing NR for this study, to the Plasma Profiling Facility team at ScilifeLab in Stockholm for generating the Olink data, Metabolon Inc. (Durham, USA) for the generation of metabolomic data and NGI Sweden for the generation of metagenomic data. The authors gratefully acknowledge the use of the services and facilities of the Koç University Research Center for Translational Medicine (KUTTAM), equally funded by the Republic of Turkey Ministry of Development Research Infrastructure Support Program. Findings, opinions, or points of view expressed in this article do not necessarily represent the official position or policies of the Ministry of Development. HY and AM acknowledge support from the PoliMeR Innovative Training Network (Marie Sklodowska-Curie Grant Agreement No. 812616) which has received funding from the European Union’s Horizon 2020 research and innovation program. The computations were performed on resources provided by SNIC through Upplands Multidisciplinary Center for Advanced Computational Science (UPPMAX) under Project SNIC 2020/16-69.

**Author contributions**

MU, JB, and AM designed the study; MZ, MA, BS, DU, and MGG recruited patients; HY, OA, MA, CF, WK, XL, JMS, CZ, SS, and JN did the experiments; HY, OA, MA, CF, WK, XL, JMS, CZ, SS, JN, and AM analyzed the data; MZ, MU, JB, and AM interpreted the data; MZ, OA, and AM wrote the manuscript; and all authors approved the final version of the manuscript.

**Conflict of interest**

AM, JB, and MU are the founder and shareholders of ScandiBio Therapeutics and ScandiEdge Therapeutics. The other authors declare no conflict of interest.

**References**


Dushay J, Chui PC, Gopalakrishnan GS, Varela-Rey M, Crawley M, Fisher FM, Badman MK, Martinez-Chantar ML, Maratos-Flier E (2010) Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. *Gastroenterology* 139: 456 – 463


Savic D, Hodson L, Neubauer S, Pavlides M (2020) The importance of the fatty acid transporter L-carnitine in non-alcoholic fatty liver disease (NAFLD). Nutrients 12: 2178


License: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.